- Carries transgene for human Group II Phospholipase A2
- Develops alopecia, epidermal hyperplasia and enlarged sebacious glands
- Exhibits an increased susceptibility to LPS induced shock and atherosclerosis
- Useful to identify and evaluate new drug candidates for treatement of human inflammatory conditions and atherosclerosis.
Genetic Background: C57BL/6
Origin: The sPLA2 mouse was developed by Xenogen Biosciences, now Taconic. The model was created by microinjecting the human sPLA2 gene into C57BL/6 x SJL zygotes. The line was subsequently backcrossed to C57BL/6NTac.
Grass, D.S., Felkner, R.H., Chiang, M., Wallace, R.E., Nevalainen, T.J., Bennett, C.F., Swanson, M.E. Expression of Human Group II PLA2 in Transgenic Mice Results in Epidermal Hyperplasia in the Absence of Inflammatory Infiltrate
, J Clin Invest., Vol. 97, No. 10, May 1996, pp. 2233-2241